(Total Views: 701)
Posted On: 11/09/2021 10:23:05 AM
Post# of 154032
gilead 1st qtr fins showing the first full quarter sales of trodelvy however a european approval is anticipated for trodelvy this dec.2021
"Trodelvy sales for the first quarter 2021 were $72 million, representing the first full quarter of sales for Gilead."
"Trodelvy sales for the second quarter 2021 were $89 million"
"Trodelvy sales for the third quarter 2021 were $101 million, reflecting increased use for the second-line treatment of metastatic triple-negative breast cancer (“TNBC”) and metastatic urothelial cancer in the United States."
"Trodelvy sales for the first quarter 2021 were $72 million, representing the first full quarter of sales for Gilead."
"Trodelvy sales for the second quarter 2021 were $89 million"
"Trodelvy sales for the third quarter 2021 were $101 million, reflecting increased use for the second-line treatment of metastatic triple-negative breast cancer (“TNBC”) and metastatic urothelial cancer in the United States."
(3)
(0)
